(CercleFinance.com) – Innate Pharma reports that it has presented data from a preliminary analysis of the Phase II Tellomak trial demonstrating clinical activity and a favorable safety profile for lacutamab, in patients with Sézary syndrome in advanced stage.
According to the biopharmaceutical company, its humanized antibody has ‘demonstrated an encouraging level of efficacy and a favorable safety profile in heavily pre-treated, post-mogamulizumab patients’ with this form of T-cell lymphoma.
The data was presented at the American Society of Hematology’s annual meeting, held in New Orleans, where Innate is showcasing its Antibody-based NK cell Engager Therapeutics (ANKET) platform via an oral presentation and posters .